|
 |
European Pharmaceutical Contractor
|
CORDIA - *EuropaBio Convention 2003 is Europe's brand new life science convention. Launching in Vienna at the end of 2003, CORDIA is not simply a conference, nor is it purely an exhibition; its sole purpose is to provide a platform to stimulate the growth of the European biotechnology industry.
Life science research in Europe is world-class, and over the last few years a vigorous entrepreneurial industry has been born of existing long-standing strengths in the science base and techniques for the production of proteins and enzymes. This nascent SME-based biotech sector is beginning to deliver tangible societal and economic benefits in health care, agriculture and the environment.
Despite this the industry is fragmented across the enlarging European Community in terms of maturity, commercialisation, intellectual property implementation, product development and management expertise, available investment, societal acceptance and local national government support. There is therefore enormous opportunity but there is also a significant challenge for the European life science industry to deliver its contribution to the EC Lisbon 2000 Summit objective of Europe becoming the "foremost knowledge-based economy by 2010". CORDIA - EuropaBio Convention 2003 is being developed through an industry steering group to deliver both top-level thinking and practical advice on the issues that are impacting growth of the European life science sector on an international stage across five core streams and three core sectors of the industry as shown.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
